Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2020 Financial and Operating Results Conference Call for March 11, 2021

Rhea-AI Summary

Asensus Surgical (NYSE American: TRXC) announced its scheduled release of fourth quarter and fiscal year 2020 financial results on March 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET, where the financial results will be discussed. Asensus focuses on pioneering Performance-Guided Surgery through its Senhance Surgical System, which integrates digital technology to improve surgical outcomes and reduce variability. Their innovative approach is available in multiple countries including the US and EU.

Positive

• Introduction of Performance-Guided Surgery could enhance surgical outcomes.
• Senhance Surgical System is now available in the US, EU, Japan, and Russia.

Negative

• None.

Asensus Surgical, Inc. (NYSE American: TRXC) (formerly TransEnterix, Inc.), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release fourth quarter and fiscal year 2020 financial and operating results after the market closes on Thursday, March 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304 for international callers, and reference conference ID 10013234 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance^® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005118/en/

FAQ

What are the financial results of Asensus Surgical for Q4 2020 and FY 2020?

Asensus Surgical plans to release its Q4 and FY 2020 financial results after market close on March 11, 2021.

When will the conference call regarding Asensus Surgical's financial results take place?

The conference call is scheduled for March 11, 2021, at 4:30 p.m. ET.

How can I access the conference call for Asensus Surgical's financial results?

To listen to the conference call, dial 1-855-327-6837 for domestic callers or 1-631-891-4304 for international callers.